{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-125170","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.667574+00:00","generated_at":"2026-06-07T14:20:15.543673+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Liquidia faces new PH-ILD patent infringement suit from United Therapeutics on '327 Patent","bullets":["United Therapeutics filed amended complaint Nov 30, 2023, alleging YUTREPIA infringes new '327 Patent covering inhaled treprostinil for PH-ILD.","The '327 Patent issued Nov 28, 2023; Liquidia argues no 30-month stay because it issued after original NDA filing.","Ongoing IPR of '793 Patent: PTAB ruled claims unpatentable; appeal pending at Federal Circuit after Dec 4, 2023 oral argument.","Liquidia intends to vigorously defend; previous Hatch-Waxman ruling still blocks YUTREPIA approval for PH-ILD."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-125170","json":"https://secwatch.observer/filing/0001104659-23-125170.json","markdown":"https://secwatch.observer/filing/0001104659-23-125170.md","text":"https://secwatch.observer/filing/0001104659-23-125170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923125170/0001104659-23-125170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923125170/tm2332679d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:20:15.543673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}